Share
The fibrotic liver disease that is associated with Biliary Atresia (BA) impacts the likelihood of survival with native liver. Our previously research demonstrated the potential for a certain profibrotic signaling pathway to be active in BA. Using a mouse model of BA and human liver gene expression data collected by ChiLDReN, we were able to confirm the likely activation of this pathway known as TWEAK/FN14 in association with liver fibrosis. We further showed that inhibition of this pathway pharmacologically was associated with near complete elimination of fibrosis in the mouse model of BA. These observations suggest that focus on this signaling pathway warrants further study as we seek novel ways to care for infants with BA.
Arbor Research Collaborative for Health has been awarded a new contract to develop and operate a secure, scalable, and innovative data registry system in support of Michigan’s Obstetrics Initiative (OBI). The initiative, one of several state-wide Collaborative Quality Initiatives (CQI), aims to improve maternal and neonatal outcomes across the state through advanced data-driven insights and
Request for Information: Arbor Research is soliciting information from qualified companies to participate in the PAn-european Registry Addressing Difelikefalin In Goal-oriented Medical treatment for dialysis-related pruritus (PARADIGM) study as the regulatory partner for Ethics Committee submission and coordination in the United Kingdom. Review details here: PARADIGM RFI UK
Arbor Research, LLC is pleased to announce the award of three domains on the GSA OASIS+ Total Small Business vehicle. Arbor Research is poised to offer solutions in the following areas: Management and Advisory Services: Providing agencies with specialized management and consulting services that improve efficiency, performance, and delivery of results. Technical and Engineering Solutions:
December 5, 2024 — Arbor Research Collaborative for Health is proud to announce an innovative collaboration with the Nephrology Associates of Northern Illinois and Indiana (NANI), the largest private nephrology practice in the United States. This partnership marks a significant milestone in advancing chronic kidney disease (CKD) research and management by leveraging NANI’s extensive patient-level